Rationale Malignant pleural mesothelioma is an almost universally fatal malignancy
primarily related to asbestos exposure. Based on the differences in immunologic markers …

Background Malignant pleural mesothelioma (MPM) is an aggressive and rare tumour with
poor prognosis. Most patients are diagnosed with advanced disease and there is a paucity …

Introduction Malignant pleural mesothelioma is an infrequent and aggressive type of cancer
that is difficult to treat, and standard therapies have shown limited effectiveness. There have …

Malignant pleural mesothelioma (MPM) is a primary and locally aggressive tumor of the
pleura. A well defined causal relationship with asbestos exposure, and an overwhelming …

Simple Summary To evaluate the best possible treatment of malignant pleural mesothelioma—
a cancer whose development is associated with asbestos exposure—an analysis of 112 …

Background: Cisplatin and pemetrexed (PEM) is the current standard in systemic therapy for
malignant pleural mesothelioma (MPM) based on the landmark randomized trial reported in …

LBA8505 Background: The vast majority of pts with PM have unresectable disease, due to
co-morbidities and/or advanced stage. In unresectable PM, standard first line treatment has …

Background Few treatment options exist for second-line treatment of malignant pleural
mesothelioma. We aimed to assess the antibody–drug conjugate anetumab ravtansine …

TPS8586 Background: Standard first line treatment for unresectable malignant pleural
mesothelioma (MPM) is platinum-based chemotherapy with pemetrexed. Two recent, single …

Background There is a strong unmet need to improve systemic therapy in mesothelioma.
Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural …